Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer

被引：0
|
作者：
Schmidt, M. [1 ]
Jackisch, C. [2 ]
Hesse, T. [3 ]
Hoffmann, O. [4 ]
Heinrich, B. J. [5 ]
Park-Simon, T-W [6 ]
Grischke, E-M. [7 ]
Weide, R. [8 ]
Mueller-Huesmann, H. [9 ]
Welslau, M. [10 ]
Wu, J. [11 ]
Schmitz, H. [12 ]
Engelbrecht, C. [13 ]
Lueck, H-J. [14 ]
机构：
[1] Univ Klinkum Mainz, Dept Gynecol, Mainz, Germany
[2] Sana Klinikum Offenbach GmbH, Dept Obstet & Gynecol, Offenbach, Germany
[3] Agaples Diakonieklinikum Rotenburg gGmbH, Dept Gynecol, Rotenburg, Germany
[4] Univ Klinikum Essen, Dept Gynecol & Obstet, Essen, Germany
[5] Praxis Heinrich Bangerter, Hematol Oncol, Augsburg, Germany
[6] MHH Hannover, Dept Gynecol, Hannover, Germany
[7] Univ Frauenklin Tubingen, Oncol, Tubingen, Germany
[8] Praxis Hamatol & Onkol Koblenz, Oncol Outpatient Dept, Koblenz, Germany
[9] Bruderkrankenhaus St Josef Paderborn, Dept Hematol Oncol, Paderborn, Germany
[10] Klinikum Aschaffenburg, Hematol Oncol, Aschaffenburg, Germany
[11] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[12] Eisai GmbH, Dept Med, Frankfurt, Germany
[13] Eisai GmbH, Med Affairs, Frankfurt, Germany
[14] Gynakol Onkol Praxis Pelikanpl, Gynecol Oncol, Hannover, Germany
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.587
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304P
引用
收藏
页码：S496 / S497
页数：2
相关论文
共 50 条
  • [21] Pharmacodynamic Model-Based Safety Management of Eribulin-Induced Myelosuppression in Patients With Breast Cancer
    Kasai, Hidefumi
    Poppenberg, Kim Linda
    Fermanelli, Valentina
    Otani, Yuki
    Tanigawara, Yusuke
    THERAPEUTIC DRUG MONITORING, 2023, 45 (03) : 318 - 326
  • [22] ERIBULIN MESYLATE (E7389) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: PHASE II NEUROPATHY DATA
    Cortes, J. A.
    Campone, M.
    Twelves, C.
    Vahdat, L. T.
    Blum, J. L.
    Rivera, R. R.
    Shuster, D. E.
    Wanders, J.
    Fang, F.
    Allison, M. A. K.
    ANNALS OF ONCOLOGY, 2008, 19 : 70 - 70
  • [23] Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin
    Sakata, Y.
    Iwata, H.
    Ikezawa, H.
    Fudetani, R.
    Tonoda, D.
    Uchida, Y.
    Hasegawa, H.
    Matsuoka, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Population Pharmacometric Analyses of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
    Majid, Oneeb
    Gupta, Anubha
    Reyderman, Larisa
    Olivo, Martin
    Hussein, Ziad
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1134 - 1143
  • [25] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
    Chen, Lan
    Yan, Xi
    Luo, Ting
    Tian, Tinglun
    He, Ping
    Zhong, Xiaorong
    CANCER MEDICINE, 2024, 13 (10):
  • [26] Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.
    Vahdat, Linda T.
    Garcia, Agustin
    Vogel, Charles L.
    Pellegrino, Christine M.
    Lindquist, Deborah L.
    Sparano, Joseph A.
    Gopalakrishna, Prashanth
    Iannotti, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [27] Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer
    Chabot, Isabelle
    Zhao, Qi
    Su, Yun
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (12) : 2025 - 2036
  • [28] Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
    Shinichiro Kashiwagi
    Wakaba Fukushima
    Yuka Asano
    Wataru Goto
    Koji Takada
    Satoru Noda
    Tsutomu Takashima
    Naoyoshi Onoda
    Masahiko Ohsawa
    Kosei Hirakawa
    Masaichi Ohira
    BMC Cancer, 17
  • [29] Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
    Kashiwagi, Shinichiro
    Fukushima, Wakaba
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Noda, Satoru
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    BMC CANCER, 2017, 17
  • [30] A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
    Liu, B.
    Liu, L.
    Ran, J.
    Xie, N.
    Li, J.
    Xiao, H.
    Yang, X.
    Tian, C.
    Wu, H.
    Lu, J.
    Gao, J.
    Hu, X.
    Cao, M.
    Shui, Z.
    Hu, Z. -y.
    Ouyang, Q.
    ESMO OPEN, 2023, 8 (03)
12345